<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755897</url>
  </required_header>
  <id_info>
    <org_study_id>CSEM GOG-002</org_study_id>
    <secondary_id>2012-GYN/CC-01</secondary_id>
    <nct_id>NCT01755897</nct_id>
  </id_info>
  <brief_title>A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients</brief_title>
  <acronym>CC-01</acronym>
  <official_title>A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will conduct a trial to determine whether paclitaxel/cisplatin (TP) as an adjuvant
      chemotherapy after radical surgery improve disease-free survival (DFS) and overall survival
      (OS), as well as the quality of life (QoL) among early-stage (FIGO stage IB-IIA) cervical
      cancer patients with risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival (DFS) of the adjuvant chemotherapy arm (arm A)</measure>
    <time_frame>up to 3-year</time_frame>
    <description>DFS was definite as the time from randomization to disease recurrence (including death from recurrence if it was the first manifestation of recurrence), death without recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DFS of the adjuvant CCRT arm (arm B)</measure>
    <time_frame>1-year DFS and 3-year DFS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survivals (OS) of the arm A and the arm B</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in two arms</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemotherapy- and radiotherapy- related adverse effects respectively in two arms</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Cervical Cancer</condition>
  <condition>Uterine Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant Chemotherapy (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel (T): 135-175 mg/m(2) intravenously (IV) on day 1, administrated intravenously over 3 hours; followed by cisplatin 75-85 mg/m(2) IV on day 2 and 3. Patients received at least 3 cycles at 4-week intervals beginning 2-3 weeks after surgery. 3-6 cycles as necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent radiochemotherapy, CCRT (Arm B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pelvic RT is delivered using IMRT technique, 45～50.4 Gy/4～7 weeks, brachytherapy will been given as necessary. Cisplatin 35 mg/m(2) IV once a week. Total treatment time is 6-7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical hysterectomy + pelvic lymph node dissection</intervention_name>
    <arm_group_label>Adjuvant Chemotherapy (Arm A)</arm_group_label>
    <arm_group_label>Concurrent radiochemotherapy, CCRT (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>135-175 mg/m(2) intravenously (IV) on day 1</description>
    <arm_group_label>Adjuvant Chemotherapy (Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m(2) IV on day 2 and 3</description>
    <arm_group_label>Adjuvant Chemotherapy (Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>35 mg/m(2) IV once a week</description>
    <arm_group_label>Concurrent radiochemotherapy, CCRT (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic RT</intervention_name>
    <description>IMRT</description>
    <arm_group_label>Concurrent radiochemotherapy, CCRT (Arm B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FIGO stage: ⅠB～ⅡA, cervical cancer;

          -  Age≤60 years; female, Chinese women;

          -  Initial treatment is radical hysterectomy + pelvic lymph node dissection;

          -  Pathological diagnosis: cervical squamous cell invasive carcinoma;

          -  Pathologic examination and meet the following one of the indications of adjuvant
             therapy: ① lymph node metastasis, ② parametrial invasion, ③ ≥ 2/3 deep stromal
             invasion, ④ histopathological grading in poorly differentiated (G2 to G3), ⑤ lymphatic
             vascular space involvement, ⑥ tumor diameter&gt; 4cm;

          -  Laboratory tests: WBC≥4×10(9)/L, NEU≥2×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤ 1.5
             times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal,
             BUN, Cr≤ normal

          -  Performance status: Karnofsky score≥60;

          -  No prior treatment;

          -  Receiving extensive resection of uterus (type III) plus pelvic lymph nodes wide
             resection; pathologically diagnosed with cervical squamous cell carcinoma;

          -  Provide written informed consent.

        Exclusion Criteria:

          -  With severe or uncontrolled internal disease, unable to receive surgery and/or
             unsuitable for radiotherapy or chemotherapy

          -  History of organ transplantation, immune diseases;

          -  History of serious mental illness, a history of brain dysfunction;

          -  Drug abuse or a history of drug abuse;

          -  Suffering from other malignancies;

          -  Concurrently participating in other clinical trials

          -  Unable or unwilling to sign informed consents;

          -  Unable or unwilling to abide by protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ding Ma, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director of Department of Gynecology and Obstetrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

